- Home
- YCBD vs BOLT Comparison
YCBD vs BOLT Comparison
Compare YCBD & BOLT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | YCBD | BOLT |
|---|---|---|
| Founded | 2015 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.0M | 7.1M |
| IPO Year | 2018 | 2021 |
Fundamental Metrics
Financial Performance| Metric | YCBD | BOLT |
|---|---|---|
| Price | $0.48 | $3.75 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 3 |
| Target Price | $2.00 | ★ $34.00 |
| AVG Volume (30 Days) | ★ 142.3K | 23.4K |
| Earning Date | 05-15-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 39.11 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $19,190,468.00 | $7,695,000.00 |
| Revenue This Year | $12.70 | N/A |
| Revenue Next Year | $7.00 | $133.33 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 0.07 |
| 52 Week Low | $0.45 | $3.13 |
| 52 Week High | $2.56 | $7.20 |
Technical Indicators
Market Signals| Indicator | YCBD | BOLT |
|---|---|---|
| Relative Strength Index (RSI) | 41.40 | 46.59 |
| Support Level | $0.47 | $3.14 |
| Resistance Level | $0.53 | $4.33 |
| Average True Range (ATR) | 0.03 | 0.29 |
| MACD | 0.00 | 0.01 |
| Stochastic Oscillator | 36.22 | 46.45 |
Price Performance
Historical ComparisonAbout YCBD cbdMD Inc.
cbdMD Inc is a United States based company. It owns and operates the consumer hemp-based cannabidiol (CBD) brand, cbdMD, Paw CBD as well as ATRx Labs brand of functional mushrooms. The company's product categories include CBD tinctures, CBD gummies, CBD topicals, CBD capsules, CBD oils, and CBD pet products. The firm distributes its products through an e-commerce website, wholesalers, and a variety of brick-and-mortar retailers.
About BOLT Bolt Biotherapeutics Inc.
Bolt Biotherapeutics Inc is a clinical-stage biopharmaceutical company developing novel immunotherapies for the treatment of cancer. The company is focused on the clinical development of BDC-4182, its claudin 18.2 ISAC. Its other pipeline programs include CEA ISAC program a Boltbody ISAC targeting carcinoembryonic antigen cell adhesion molecule 5, or CEA; PD-L1 ISAC utilizes a novel human anti-PD-L1 antibody conjugated to a next-generation TLR7/8 agonist payload via a non-cleavable linker; and BDC-3042, its dectin-2 agonist antibody program, developed to repolarize critical cells in the tumor microenvironment known as tumor associated macrophages. It operates in single segment.